TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma Limited has increased its stake in LevOmega Pty Ltd to approximately 43% through a strategic A$1 million investment. This move aims to bolster LevOmega’s development of sustainable, pharmaceutical-grade omega-3 products, addressing the global demand for alternatives to traditional fish oil sources, which face sustainability challenges. The investment aligns with LTR Pharma’s strategy to support scalable solutions for global sustainability issues while complementing its core pharmaceutical pipeline.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies for unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized treatments in Australia and is expanding into the US and other markets. Its lead products include SPONTAN® and ROXUS®, intranasal sprays for erectile dysfunction, and OROFLOW®, under development for Oesophageal Motility Disorders.
Average Trading Volume: 889,266
Technical Sentiment Signal: Strong Buy
See more insights into LTP stock on TipRanks’ Stock Analysis page.